Sunil Patel, MD
Hematology & Oncology · Texarkana, TXNPI 1588715916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 631 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,503 and has fallen 86.0% since, to $349 in 2025.
Across 631 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$886
- Pfizer$758
- Coherus Oncology, Inc.$695
- Merck$629
- Novartis$585
- Johnson & Johnson$584
- plus $7K from 54 others
Across 5 payments — averaging $3209.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$15K
- Caris MPI, Inc.$1K
- AbbVie$90
What the payments were for
- Food & beverage$11,21093%
- Education$7997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,008 in reported general payments places this provider in the 75th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 49 | $741,286 |
| PomalystPomalidomide | 25 | $573,480 |
| RevlimidLenalidomide | 33 | $503,551 |
| NinlaroIxazomib Citrate | 34 | $435,270 |
| TagrissoOsimertinib Mesylate | 20 | $334,348 |
| CabometyxCabozantinib S-Malate | 16 | $313,634 |
| XtandiEnzalutamide | 23 | $263,499 |
| Abiraterone Acetate | 96 | $249,492 |
| MekinistTrametinib Dimethyl Sulfoxide | 17 | $238,398 |
| JakafiRuxolitinib Phosphate | 13 | $226,037 |
| ImbruvicaIbrutinib | 12 | $220,207 |
| LonsurfTrifluridine/Tipiracil Hcl | 18 | $214,880 |
| TafinlarDabrafenib Mesylate | 17 | $197,686 |
| VenclextaVenetoclax | 30 | $153,535 |
| IbrancePalbociclib | 12 | $131,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $758 | $952,212177 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $309 | $573,48025 claims |
| Bristol Myers SquibbRevlimid | $320 | $503,55133 claims |
| NovartisMekinist, Tafinlar | $585 | $436,08434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $304 | $435,27034 claims |
| AstraZenecaTagrisso | $474 | $334,34820 claims |
| Exelixis Inc.Cabometyx | $216 | $313,63416 claims |
| Astellas Pharma US IncXtandi | $177 | $263,49923 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $29 | $249,49296 claims |
| Incyte CorporationJakafi | $475 | $226,03713 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $148 | $220,20712 claims |
| Taiho Oncology, Inc.Lonsurf | $124 | $214,88018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Texarkana
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.